Abstract: Objective The aim of this study was to summarize clinical feature of patients with drug-induced liver injury (DILI) in order to improve clinical management. Methods 230 patients with DILI were encountered in our hospital between March 2020 and March 2023, and the demographic data, clinical manifestations, and clinical tests were retrospectively reviewed and summarized. Serum antinuclear antibody (ANA) was assayed by Western blot, and serum IgG and IgM were detected routinely. Results Of 230 patients with DILI, obesity accounted for 45.7%, diabetes type 2 for 37.8% and hyperlipidemia for 43.5%; as for underlying diseases, infection accounted for 23.5%, cardiovascular diseases for 17.0% and tumor for 13.0%; patients with hepatocellular injury accounted for 61.7%, cholestatic injury for 24.4% and mixed type for 13.9%; one single alleged medicines accounted for 58.3%, double for 22.6%, trible for 13.0% and quadruplex for 6.1%; mild to moderate liver injury accounted for 58.7% and severe for 41.3%; serum IgM and IgG levels were normal, and serum ANA positive for 27.5%; all patients in our series recovered without death. Conclusion Patients with DILI in our series is relatively young, inappropriate medication might be involved in pathogenesis and the prognosis is good.

Key words: Drug-induced liver injury, Clinical feature, Prognosis